Online inquiry

IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ12635MR)

This product GTTS-WQ12635MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets RSPO3 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_032784.5
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	84870
UniProt ID	Q9BXY4

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12635MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ14002MR	IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	REGN-3470-3471-3479
GTTS-WQ14684MR	IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	SCT-400
GTTS-WQ12468MR	IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	NN-8226
GTTS-WQ5011MR	IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	c4G7-N
GTTS-WQ11525MR	IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	MFGR1877S
GTTS-WQ7883MR	IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	GSK-249320
GTTS-WQ662MR	IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	8H9
GTTS-WQ2538MR	IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	AMG 477

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST